Now, investigators from Germany at the University of Erlangen, the Max Delbr ck Center for Molecular Medicine (MDC) Berlin-Buch and Regensburg, collaborating with researchers from Finland and Austria have shed new light on the relationship between salt intake, bodily processes, and blood pressure regulation. Within the skin, they have detected a new storage area for salt in the body. They also found out that if the process behind this storage is defect, animals become hypertensive (Nature Medicine, doi 10.1038/nm.1960).

Salt (natrium chloride, NaCl) is required for life. Herbivores (plant-eating animals) risk their lives to go to "salt licks" and carnivores (meat-eating animals) go to salt licks to eat herbivores in order to obtain salt.

Salt is responsible for water regulation in the body. It is taken up by the gastro-intestinal (GI) tract and, in large part, excreted by the kidneys. However, salt is also stored in cells and in the interstitium, the area between cells in the body.

Dr. Jens Titze and colleages, among them Dominik N. M ller, Wolfgang Derer, and Friedrich C. Luft from the Experimental and Clinical Research Center at the MDC, could now show that a high-salt diet in rats leads to the accumulation of salt in the interstitium in the skin. This process is carefully regulated by special white blood cells, the macrophages.

In those macrophages, the scientists found a gene regulator (transcription factor) called TonEBP (tonicity-responsible enhancer binding protein). TonEBP is activated in these cells in response to high salt and turns on a gene (VEGF-C - vascular endothelial growth factor C) that controls the production of lymphatic blood vessels. With high-salt diet the lymphatic vessels increase.

The investigators also showed that when these macrophages are depleted or if the receptor for VEGF-C is absent, the animals are not able to "store their salt" and become hypertensive. However, this process and its relevance to human disease are not yet completely understood.

helmholtz.de/

Protein biomarker discovery: Proteomic Analysis of Lung Cancer Cell Lines (PI: Hanash) Tumor biomarker discovery: Biomarker Discovery for Lung Cancer in Never Smokers (PI: Gazdar) Genome analysis: Genomic Studies of Lung Cancer Cell Lines from Lung Cancers Arising in Current, and Never Smokers (PIs: Lam and Lam) RNA analysis: MicroRNA Profiles of a Lung Cancer Cell Line Panel (PI: Muneesh Tewari, Fred Hutchinson Cancer Center, Seattle, Wash.) Genome analysis: Genome-Wide DNA Methylation Profiling of Lung Adenocarcinomas from Never Smokers and Current Smokers (PI: Ite Laird-Offringa, University of Southern California, Los Angeles)

"This project is extremely important, both in its approach toward lung cancer detection and in its structure as a multi-institutional, transdisciplinary project funded through a public-private partnership," said John E. Niederhuber, M.D., director of the National Cancer Institute. "Identification of biomarkers, which tell us who is at risk for cancer and help diagnose cancer at the earliest possible stages, is an important priority in cancer prevention research and a key component in efforts to reduce the burden of this disease."

Canary Foundation is a non-profit dedicated to the goal of identifying cancer early through a simple blood test and then isolating it with imaging. Since 2004, Canary has raised over $30 million in pledges towards its initial goal of $50 million for early detection research. Its collaborative research programs span multiple disciplines and institutions. 100 percent of donations go to early detection research activities. For more information, please visit wwwnaryfoundation.

NCI leads the National Cancer Program and the NIH effort to dramatically reduce the burden of cancer and improve the lives of cancer patients and their families, through research into prevention and cancer biology, the development of new interventions, and the training and mentoring of new researchers. For more information about cancer, please visit the NCI Web site at cancer or call NCI's Cancer Information Service at 1-800-4-CANCER (1-800-422-6237).

The NCI's Early Detection Research Network (EDRN) brings together dozens of institutions to help accelerate the translation of biomarker information into clinical applications and to evaluate new ways of testing cancer in its earliest stages and for cancer risk. For more information, please visit edrn.nci.nih/.